More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as front-line treatment remain in remission seven years later, researchers have reported.
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as front-line treatment remain in remission seven years later, researchers have reported.